Truist lowered the firm’s price target on Tourmaline Bio (TRML) to $63 from $74 but keeps a Buy rating on the shares. The firm is also raising its FY25 EPS view to ($3.65) from ($4.45). Truist is updating its model to reflect Pacibekitug opportunity in ASCVD, atherosclerotic cardiovascular disease, which represents significant upside to the company, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Truist biotech analyst holds an analyst/industry conference call
- Tourmaline Bio’s TOUR006: Potential Best-in-Class IL-6 Treatment with Strategic Market Positioning
- Positive Buy Rating for Tourmaline Bio Driven by Promising Pacibekitug Developments and Strategic Value
- Tourmaline Bio price target raised to $43 from $42 at Wedbush
- Buy Rating for Tourmaline Bio: Potential of Pacibekitug and Upcoming CKD Data Release